Chek the Channels
Dyadic International Inc. (DYAI)
Established Another Partnership in China
Dyadic International Inc. is a biotechnology company developing a proprietary C1 expression platform to express and manufacture biologic products. The C1 technology is part of a fungi expression system, which utilizes inexpensive substrates yielding a high level of production. Dyadic is currently improving and optimizing the production of biological products in a C1 expression system. The company’s partnership portfolio with pharmaceutical and institutions includes Zapi Project, Israel Institute for Biological Research, Mitsubishi Tanabe Pharma, Sanofi-Aventis covering the production of a diverse range of biologics, such as monoclonal antibodies, bispecific and Fc-fusion proteins. Dyadic also established a sub-licensing agreement with an Australian based drug development and contract manufacturing firm, Luina Bio, to utilize C1 platform for the development and commercialization of biological products to prevent and treat animal diseases. Company’s C1 bioenergy business was sold to Dupond Industrial Biosciences (DuPont) for $75 mm in 2015 granting the company the rights to use C1 platform in biopharma applications.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Dyadic added another company to its partnership portfolio. Dyadic entered into a nonexclusive research collaboration with WuXi Biologics to evaluate the C1 technology in a cGMP facility and to perform experiments with the C1 cell lines for any other internal noncommercial purposes. WuXi Biologics is a China-headquartered biologics discovery, development, and manufacturing company. The current portfolio expanded to ten partnerships assessing the C1 platform in biologics manufacturing.
What do these partnerships mean for Dyadic? The company implements a business model where the C1 expression system is being assessed in multiple biologic modalities (vaccines, gene therapy, antibodies, and others) by multiple partners (Sanofi, Zapi, Serum India, and others). By implementing this business model, Dyadic is keeping its cash burn at a minimum, while diversifying the C1’s portfolio and potentially increasing its probability of success. The company is also...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.